Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Muscle Relaxant Drugs Market Be Worth By 2029?

The market size for muscle relaxant drugs has seen a robust growth in the last few years. The market which was valued at $4.77 billion in 2024 is expected to expand to $5.11 billion in 2025, witnessing a compound annual growth rate (CAGR) of 7.0%. The historical growth is credited to the alteration in treatment methodologies, management of chronic pain, advancements in pharmaceutical drug formulations, surge in surgical operations and the widening scope of physical rehabilitation practices.

In the coming years, the market size of muscle relaxant drugs is anticipated to witness significant growth, with an expected value of “$6.9 billion in 2029,” expanding at a compound annual growth rate (CAGR) of 7.8%. This expected growth in the forecasted period is due to factors such as comprehensive pain management strategies, an increasing elderly population, chronic diseases, research into targeted therapies, emphasis on non-medical pain relief, and progress in pain management treatments. Key trends for the forecast period include improvements in the side effect profiles, personalized medication strategy, research in substitute therapies, incorporation of muscle relaxants in pain management procedures, and the emergence of botulinum toxin injections.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8751&type=smp

What Drivers Are Accelerating Expansion Of The Muscle Relaxant Drugs Market?

The anticipated growth of the muscle relaxant drugs market can be largely attributed to the increasing geriatric population. Essentially, this demographic refers to individuals aged 65 and above, who are more prone to musculoskeletal disorders, leading to heavier reliance on muscle relaxant drugs for relief and sedation. Notably, as reported by the World Health Organization (a Switzerland-based global public health agency) in October 2022, the worldwide count of individuals aged 60 and above is forecasted to rise from 1 billion in 2020 to 1.4 billion by 2022. Additionally, by the year 2030, every 6th person globally will be over the age of 60. Given this, the mounting geriatric population is a key factor propelling the expansion of the muscle relaxant drugs market.

Which Segmentation Categories Are Highlighted In The Muscle Relaxant Drugs Market Analysis?

The muscle relaxant drugs market covered in this report is segmented –

1) By Drug Type: Facial Muscle Relaxant Drugs, Skeletal Muscle Relaxant Drugs, Neuromuscular Blocking Agents

2) By Formulation: Cyclobenzaprine, Carisoprodol, Chlorzoxazone, Metaxalone, Methocarbamol, Baclofen, Tizanidine, Orphenadrine, Dantrolene

3) By Route Of Administration: Oral, Injectable, Spray, Ointment

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Facial Muscle Relaxant Drugs: Botulinum Toxin, Dysport, Xeomin

2) By Skeletal Muscle Relaxant Drugs: Centrally Acting Muscle Relaxants, Peripherally Acting Muscle Relaxants

3) By Neuromuscular Blocking Agents: Non-Depolarizing Agents, Depolarizing Agents

Which Market Trends Are Expected To Define The Future Of The Muscle Relaxant Drugs Market?

Trend 1

Enacting product innovations is emerging as a prevalent trend in the muscle relaxant drug market. Major players in this field are capitalizing on creating groundbreaking drugs geared towards specific medical uses, like generic muscle relaxant drugs, muscle relaxants for the animal sector, drugs offering adaptable, personalized dosing, and more, all with the aim of maintaining their market stance. To illustrate, Amneal Pharmaceuticals Inc., an integrated specialty pharmaceutical firm based in the US, introduced LYVISPAH in June 2022, an FDA-approved baclofen oral granule (5, 10, and 20 mg) specialty product intended for addressing spasticity resulting from multiple sclerosis or other spinal cord conditions. LYVISPAH offers personalizable dosing flexibility with 5 mg, 10 mg, and 20 mg single-dose granule packets to help manage muscle stiffness, spasms, and pain caused by multiple sclerosis. The fast-dissolving flavored granules serve as an alternative for spasticity patients who find pill swallowing challenging. The product can be administered in three ways: directly into the patient’s mouth with or without water, mixed with liquids or foods, or via an enteral feeding tube.

Who Are The Dominant Players In The Muscle Relaxant Drugs Market Today?

Major companies operating in the muscle relaxant drugs market are Pfizer Inc., Ipsen Pharma SA, Teijin Limited, Par Pharmaceutical Companies Inc., Orient Phaarma Co. Ltd., Novartis AG, Accord Healthcare Ltd., Amneal Pharmaceuticals LLC, Fresenius Kabi India Pvt. Ltd., Aurobindo Pharma Ltd., Mylan NV, Hikma Pharmaceuticals PLC, Akorn Incorporated, Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd., Lifesciences Limited, Neurana Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Lannett Company Inc., Unichem Laboratories, SteriMax Inc., Endo Pharmaceuticals Inc., Abbvie Inc., Merz Pharmaceuticals LLC, Vertical Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Eisai Co. Ltd., Metacel Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd., Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Muscle Relaxant Drugs Market?

North America was the largest region in the muscle relaxant drugs market share in 2024. The regions covered in the muscle relaxant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8751&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model